Mifegyne (Mifepristone)

Mifepristone binds competitively to progesterone receptors in the uterus, blocking the hormone’s action that maintains the endometrial lining. This antagonism leads to decidual breakdown, cervical softening, and sensitisation of the uterus to prostaglandins, facilitating expulsion of the conceptus. It also antagonises glucocorticoid receptors, which underlies its off‑label use in Cushing’s syndrome.

The specific dose of Mifegyne is determined by the prescribing clinician based on the approved protocol for the intended indication, gestational age, and patient factors. In the standard medical abortion regimen, a single 200 mg oral tablet is commonly used, but the exact regimen should be confirmed by the treating physician.

Mifegyne is contraindicated in ongoing pregnancy beyond the approved gestational limit and is classified as pregnancy category X because it terminates pregnancy. It is also not recommended for breastfeeding women, as mifepristone can be excreted in milk and may affect the infant. Women should discuss alternatives with their healthcare provider.

To request Mifegyne, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature requirements) and assistance with import documentation.

The most common alternative to Mifegyne in medical abortion is misoprostol, which is a prostaglandin analogue that induces uterine contractions. Mifegyne initiates the process by antagonising progesterone, creating a receptive uterine environment, while misoprostol completes the expulsion. Using both drugs sequentially is standard practice, offering higher efficacy than misoprostol alone.

Mifegyne tablets should be stored at ambient temperature, preferably below 25 °C, in their original blister pack to protect from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or near heat sources. No refrigeration is required for this oral tablet formulation.

Mifegyne is taken orally as a single tablet, usually under direct supervision of a qualified healthcare professional. After ingestion, a follow‑up dose of misoprostol is typically prescribed 24–48 hours later to complete the abortion process. The exact administration schedule, including timing and route of any additional medication, is defined by the treating clinician.

The most serious adverse events include heavy or uncontrolled uterine bleeding that may require transfusion, infection, and rare cases of uterine rupture. Allergic reactions such as anaphylaxis can also occur. Patients should be monitored closely for signs of severe bleeding, fever, or abdominal pain and seek immediate medical attention if these arise.

Mifegyne is contraindicated in women with confirmed ectopic pregnancy, chronic adrenal insufficiency, anticoagulant therapy, known hypersensitivity to mifepristone, or when the gestational age exceeds 49 days. It should also be avoided in patients with severe cardiovascular disease or uncontrolled hypertension. A thorough medical assessment is required before prescribing.